Maxim Group Initiates Coverage On Kiora Pharmaceuticals with Buy Rating, Announces Price Target of $2.5
Yesterday, 9:20 AM
Maxim Group analyst Jason McCarthy initiates coverage on Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy rating and announces Price Target of $2.5.
January 14, 5:31 PM
Gainers Avinger (NASDAQ:AVGR) stock moved upwards by 9.7% to $0.34 during Friday's after-market session. This security traded at a volume of 1.2 million shares come close, making up 60.0% of its average volume over the last 100 days. The company's market cap stands at $32.6 million.
January 11, 5:42 PM
January 5, 7:15 PM
Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference
January 5, 8:08 AM
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Brian M Strem, Ph.D., President and Chief Executive Officer, will provide an outlook for the busines and its pipeline of treatments for ophthalmic diseases.
January 4, 6:06 AM
Gainers Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa Immunogene combination therapy.
December 31, 4:35 AM
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.